Who are enfortumab vedotin (EV)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Padcev Ejfv, ENFORTUMAB VEDOTIN, Enfortumab, Padcev, Zilovertamab vedotin, gemtuzumab ozogamycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/enfortumab-vedotin-ev.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

enfortumab vedotin (EV) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

enfortumab vedotin (EV) (enfortumab vedotin (EV)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody-drug conjugate. Area: Oncology.

phase 3 Monoclonal antibody-drug conjugate Nectin-4 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

enfortumab vedotin (EV) (enfortumab vedotin (EV)) — Astellas Pharma Global Development, Inc.. Enfortumab vedotin is a monoclonal antibody-drug conjugate that targets Nectin-4, a protein highly expressed on the surface of certain cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
enfortumab vedotin (EV) TARGET	enfortumab vedotin (EV)	Astellas Pharma Global Development, Inc.	phase 3	Monoclonal antibody-drug conjugate	Nectin-4
Padcev Ejfv	enfortumab-vedotin	Astellas Pharma	marketed		Nectin-4	2019-01-01
ENFORTUMAB VEDOTIN	ENFORTUMAB VEDOTIN		marketed		Nectin-4	2019-01-01
Enfortumab	padcev	Astellas Pharma	marketed		Nectin-4	2019-01-01
Padcev	AGS-22M6E	Astellas Pharma	marketed		Nectin-4	2019-01-01
Zilovertamab vedotin	Zilovertamab vedotin	Merck Sharp & Dohme LLC	phase 3	Monoclonal antibody-drug conjugate	CD30
gemtuzumab ozogamycin	gemtuzumab ozogamycin	Nantes University Hospital	phase 3	Monoclonal antibody-drug conjugate (ADC)	CD33

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody-drug conjugate class)

GlaxoSmithKline · 2 drugs in this class
RemeGen Co., Ltd. · 2 drugs in this class
Copharos · 1 drug in this class
Eastern Cooperative Oncology Group · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Mirati Therapeutics Inc. · 1 drug in this class
NYU Langone Health · 1 drug in this class
The Lymphoma Academic Research Organisation · 1 drug in this class
Astellas Pharma Global Development, Inc. · 1 drug in this class
Yan Zhang, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). enfortumab vedotin (EV) — Competitive Intelligence Brief. https://druglandscape.com/ci/enfortumab-vedotin-ev. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab